Sight Sciences (NASDAQ:SGHT) Insider Jeremy Hayden Sells 6,308 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy Hayden sold 6,308 shares of Sight Sciences stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $6.62, for a total value of $41,758.96. Following the sale, the insider owned 267,611 shares of the company’s stock, valued at approximately $1,771,584.82. This trade represents a 2.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Sight Sciences Stock Up 2.2%

Shares of NASDAQ SGHT opened at $6.38 on Thursday. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62. The business has a 50-day moving average of $7.78 and a 200-day moving average of $5.33. The firm has a market capitalization of $337.31 million, a price-to-earnings ratio of -7.09 and a beta of 2.42. Sight Sciences, Inc. has a 12 month low of $2.03 and a 12 month high of $9.24.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, November 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.10. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The business had revenue of $19.91 million during the quarter, compared to analyst estimates of $17.74 million. Sell-side analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SGHT has been the subject of several research analyst reports. Piper Sandler set a $9.00 price target on Sight Sciences in a research note on Monday, January 5th. UBS Group raised their price objective on Sight Sciences from $7.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Citigroup upped their target price on Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a research note on Monday, January 5th. Finally, Morgan Stanley boosted their price objective on shares of Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 2nd. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Sight Sciences presently has an average rating of “Hold” and an average price target of $8.30.

Hedge Funds Weigh In On Sight Sciences

A number of large investors have recently bought and sold shares of the stock. AQR Capital Management LLC purchased a new stake in shares of Sight Sciences during the first quarter valued at approximately $128,000. Strs Ohio purchased a new stake in Sight Sciences during the 1st quarter valued at $158,000. Rhumbline Advisers boosted its position in Sight Sciences by 9.5% during the 1st quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock valued at $120,000 after buying an additional 4,319 shares during the period. Palumbo Wealth Management LLC bought a new stake in Sight Sciences in the 2nd quarter worth $328,000. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Sight Sciences by 38.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock valued at $66,000 after acquiring an additional 4,453 shares during the period. 55.51% of the stock is owned by hedge funds and other institutional investors.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.